Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
— Phase 1/2 Multi-Center Clinical Trial to Begin Enrolling in Q4 2019 — SANTA MONICA, Calif. & BURLINGAME, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (Nasdaq:...